Hims & Hers Health saw its stock drop by over 9% in after-hours trading following the release of its first-quarter earnings, which revealed a revenue of $608.1 million, falling short of analysts' expectations of $616.85 million. The company also reported a surprising loss of 40 cents per share, contrasting with the anticipated profit of 4 cents per share. This decline in performance is attributed to a strategic shift towards personalized treatments and regulatory challenges surrounding GLP-1 weight-loss drugs in the United States. Chief Financial Officer Yemi Okupe indicated that while there is early demand for their new GLP-1 products, the average monthly revenue per subscriber has decreased from $85 to $80 year-over-year, reflecting reduced consumer spending. Despite these challenges, Hims raised its full-year revenue forecast to between $2.8 billion and $3 billion, up from a previous estimate of $2.7 billion to $2.9 billion. The company also expects second-quarter revenue to be between $680 million and $700 million, exceeding analysts' expectations of $642.95 million.